title: No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients.
abstract: BACKGROUND
  Ozone as a strong oxidant may induce an inflammatory response.
  
  
  OBJECTIVE
  The hypothesis was verified as to whether ozonated autohemotherapy using an ozone dose in therapeutic range changes the plasma concentration of C-reactive protein and interleukin-6, markers of inflammation.
  
  
  METHODS
  In a controlled, single-blind, cross-over study, 12 chronically hemodialyzed patients with peripheral arterial disease were exposed to nine sessions of autohemotherapy with blood exposure to oxygen as a control followed by nine sessions of ozonated autohemotherapy with an ozone concentration of 50 microg/ml.
  
  
  RESULTS
  There was no statistical difference between C-reactive protein levels at baseline (1.53 +/- 1.01 mg/l), after nine sessions of control autohemotherapy (1.48 +/- 0.96 mg/l), and after nine sessions of ozonated autohemotherapy (1.55 +/- 0.84 mg/l). There was also no statistical difference between the interleukin-6 serum concentration at baseline (438 +/- 118 pg/ml), after nine sessions of control autohemotherapy (444 +/- 120 pg/ml), and after nine sessions of ozonated autohemotherapy (466 +/- 152 pg/ml).
  
  
  CONCLUSIONS
  The results of this study suggest that ozonated autohemotherapy using an ozone concentration of 50 microg/ml does not induce an inflammatory response.
authors.affiliation: Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, ul. Debinki 7, 80-211 Gdansk, Poland. leszek.tylicki@amg.gda.pl
authors.forename: Leszek
authors.initials: L
authors.lastname: Tylicki
authors.forename: Bogdan
authors.initials: B
authors.lastname: Biedunkiewicz
authors.forename: Dominik
authors.initials: D
authors.lastname: Rachon
authors.forename: Tomasz
authors.initials: T
authors.lastname: Nieweglowski
authors.forename: Lukasz
authors.initials: L
authors.lastname: Hak
authors.forename: Andrzej
authors.initials: A
authors.lastname: Chamienia
authors.forename: Alicja
authors.initials: A
authors.lastname: Debska-Slizien
authors.forename: Ewa
authors.initials: E
authors.lastname: Aleksandrowicz
authors.forename: Jolanta
authors.initials: J
authors.lastname: Mysliwska
authors.forename: Boleslaw
authors.initials: B
authors.lastname: Rutkowski
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism; D018592:Cross-Over Studies; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000097:blood; D010126:Ozone / Q000009:adverse effects / Q000627:therapeutic use*; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000188:drug therapy; D006435:Renal Dialysis; D012449:Safety; D016037:Single-Blind Method
chemical_list: D018836:Inflammation Mediators; D015850:Interleukin-6; D010126:Ozone; D002097:C-Reactive Protein